

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

117-231

SERIAL NO.
(To Be Assigned)

APPLICANT

MACLEAN et al

FILING DATE

28 January 1997

GROUP

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
Sue	4,859,587	08/22/89	ROIZMAN, Bernard			
J	5,328,688	07/12/94	ROIZMAN, Bernard			

FOREIGN PATENT DOCUMENTS

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, etc.)

See	NEUROSURGERY, Vol. 32, NO. 4, April 1993; pp 597-603, MARKERT et al; 'Reduction and Elimination of Encephalitis in an Experimental Glioma Therapy Model with Attenuated Herpes Simplex Mutants that Retain et al'
✓	SCIENCE, Vol. 250, 1990; pp 1262-1266; CHOU et al; 'Mapping of Herpes Simplex Virus-1 Neurovirulence to v.34.5, a Gene Nonessential for Growth in Culture'
	VIROL 70, (1989), pp 705-716; TAHIA et al; 'A Variant of Herpes Simplex Virus Type 2 Strain HG52 with a 1.5 kb Deletion in R, between 0 to 0.02 and 0.81 to 0.83 Map Units Is Non-neurovirulent for Mice'
	GENE THERAPY 1, 1994, PP 323-331; BOVIATSIS et al; 'Antitumor activity and reporter gene transfer into rat brain neoplasms inoculated with herpes simplex virus vectors defective in thymidine kinase or et al'
	VIROL. 69, 1988, PP 1531-1574; McGEOCH et al; 'The Complete DNA Sequence of the Long Unique Region in the Genome of Herpes Simplex Virus Type 1'
	NAT. ACAD. SCI. USA; Vol 86, pp 4736-4740; COEN et al; 'Thymidine kinase-negative herpes simplex virus mutants establish latency in mouse trigeminal ganglia but do not reactivate'
	SCIENCE 252; 1991, PP 854-856; MARTUZA et al; 'Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant'

***Examiner**

A. G.

Date Considered

3/8/98

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to applicant.

Form PTO-FB-A820 (Also PTO-1449)